Biodexa Pharmaceuticals (BDRX) Other Non-Current Assets (2018)
Biodexa Pharmaceuticals' (BDRX) quarterly Other Non-Current Assets came in at $12.0 million in Q4 2018, down 34.75% quarter-over-quarter from $18.4 million in Q2 2018.
Powered by 
Analysis
Biodexa Pharmaceuticals (BDRX) Other Non-Current Assets (2018) Analysis & Trends
Biodexa Pharmaceuticals has disclosed Other Non-Current Assets across 1 years of filings, most recently posting $12.0 million for Q4 2018.
- In Q4 2018, Other Non-Current Assets changed N/A year-over-year to $12.0 million; the TTM figure through Dec 2018 stood at $12.0 million (changed N/A YoY), while the FY2018 annual figure was $12.5 million, changed N/A from the prior year.
- Other Non-Current Assets came in at $12.0 million for Q4 2018 at Biodexa Pharmaceuticals, down from $18.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $18.4 million in Q2 2018 to a low of $12.0 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Biodexa Pharmaceuticals | 53.69 Mn | 42.34 Mn | - | - |